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Abstract
Elevated low-density lipoprotein (LDL) levels induce acti-
vation of the p38 mitogen-activated protein kinase
(MAPK), a stress-activated protein kinase potentially par-
ticipating in the development of atherosclerosis. The
nature of the lipoprotein components inducing p38
MAPK activation has remained unclear however. We
show here that both LDLs and high-density lipoproteins
(HDLs) have the ability to stimulate the p38 MAPKs with
potencies that correlate with their cholesterol content.
Cholesterol solubilized in methyl-b-cyclodextrin was suf-
ficient to activate the p38 MAPK pathway. Liposomes
made of phosphatidylcholine (PC) or sphingomyelin, the
two main phospholipids found in lipoproteins, were un-
able to stimulate the p38 MAPKs. In contrast, PC lipo-
somes loaded with cholesterol potently activated this
pathway. Reducing the cholesterol content of LDL par-
ticles lowered their ability to activate the p38 MAPKs.
Cell lines representative of the three main cell types
found in blood vessels (endothelial cells, smooth muscle
cells and fibroblasts) all activated their p38 MAPK path-
way in response to LDLs or cholesterol-loaded PC lipo-
somes. These results indicate that elevated cholesterol
content in lipoproteins, as seen in hypercholesterolemia,
favors the activation of the stress-activated p38 MAPK
pathway in cells from the vessel wall, an event that might
contribute to the development of atherosclerosis.
Keywords: cholesterol; HDL; LDL; lipoproteins; p38
MAPK; signal transduction.
Introduction
The best described physiological function of LDLs is to
transport cholesterol to target tissues (Dietschy and Tur-
The last two authors share senior authorship.a
ley, 2002). LDLs deliver their cholesterol cargo to cells
following their interaction with the LDL receptor (Dietschy
and Turley, 2002). LDLs, when their vascular concentra-
tions increase, have also been implicated in pathologies
such as atherosclerosis. Elevation of LDL levels in plas-
ma results in their retention and accumulation in ather-
osclerotic plaques (Glass and Witztum, 2001). The
presence of LDLs in plaques apparently modulates their
stability and can favor rupture of the fibrous cap and
deposition of thrombus leading to acute myocardial
infarction (LaBelle and Tulenko, 2004).
Besides their function as cholesterol carriers, LDLs
have the potential to activate different intracellular sig-
naling pathways such as the p38, the c-Jun N-terminal
kinase (JNK) and the extracellular signal-regulated kinase
(ERK) MAPKs, protein kinase C (PKC), G-proteins and
cAMP (Gouni-Berthold and Sachinidis, 2002). The impli-
cation of these various cellular pathways in the physio-
logical and pathological functions of LDLs is unclear at
the present time.
The ability of LDLs to activate the p38 MAPK pathway
has been observed in various cell types. For example,
LDLs induce activation of the p38 MAPKs in human
umbilical vein endothelial cells (HUVEC) (Zhu et al., 2001),
vascular smooth muscle cells (VSMC) (Gouni-Berthold
et al., 2001; Gouni-Berthold and Sachinidis, 2002), and
fibroblasts (Dobreva et al., 2003). Activation of the p38
MAPK pathway was shown to be important for the upre-
gulation of endothelial genes implicated in atherogenesis
(Zhu et al., 2001), VSMC growth (Gouni-Berthold et al.,
2001; Gouni-Berthold and Sachinidis, 2002), and fibro-
blast spreading (Dobreva et al., 2003), mechanisms that
could be potentially involved in the complications of ath-
erosclerosis. Relatively little is known however on the
mechanisms that allow LDLs to activate the p38 MAPK
pathway. The LDL receptor does not seem to be involved
as cells lacking functional LDL receptors have the same
ability as control cells to induce the p38 MAPK pathway
in response to LDLs (Dobreva et al., 2003). Thus, char-
acterization of the LDL components involved in the
induction of the p38 MAPK pathway would contribute to
a better understanding of the signaling properties of
lipoproteins.
LDL particles are high molecular weight complexes
made of esterified and non-esterified cholesterol, various
phospholipids, triglycerides (TGs) and a single copy of
apolipoprotein B-100 (Hevonoja et al., 2000). The pres-
ence of multiple components in LDL particles, the fact
that these compounds can be oxidized and acquire new
properties, and the observation that LDLs can carry trace
amounts of bioactive molecules such as lysophosphati-
dylcholine, phosphatidylethanolamine, diacylglycerol,
ceramide and some phosphoinositides (Hevonoja et al.,
2000), has greatly complicated the identification of the
relevant LDL components that mediate activation of the
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p38 MAPKs. Here, we present evidence that cholesterol
is the main component in native lipoproteins that medi-
ates their ability to stimulate the p38 MAPK pathway.
Results
Correlation between the amount of cholesterol in
lipoproteins and their ability to stimulate the p38
MAPK pathway
To assess whether there is a shared component among
various lipoprotein fractions that mediates activation of
the p38 MAPK, we compared the ability of LDLs and
HDLs to stimulate this pathway. As shown in Figure 1A,
both lipoproteins activated the p38 MAPK pathway.
Since HDLs and LDLs have a different protein compo-
sition (LDLs contain apolipoprotein B-100 and HDLs con-
tain apolipoproteins A, C, D, E and J), this indicates that
the protein moiety of lipoproteins is unlikely to mediate
the activation of the p38 MAPKs. In support of this notion
is the observation that the two lipoproteins display dif-
ferent potencies in the activation of the p38 MAPK path-
way when their concentration is expressed in terms of
mg/ml protein (Figure 1B).
If there is a shared component in the two lipoproteins
that mediates the p38 response, similar dose-response
curves should be obtained when their ability to activate
the p38 MAPKs is expressed as a function of the con-
centration of the shared component. The activation of the
p38 MAPKs by LDLs and HDLs determined in Figure 1B
was therefore expressed as a function of the theoretical
concentrations of various components present in both
lipoproteins wphospholipids, cholesterol, TGs (Kritchev-
sky, 1986) and sphingosine-1-phosphate (S1P) (Okajima,
2002)x (Figure 1C). The data were also expressed as
a function of particle concentration (Ginsberg and
Goldberg, 1998) to determine whether the p38 MAPK
response is proportional to the number of lipoprotein par-
ticles. Figure 1D shows that LDL and HDL had the same
potency in inducing p38 MAPKs when cholesterol, but
not the other components, was used to express their
concentration. Moreover, when the stimulation of the p38
MAPKs by LDLs and HDLs was plotted against the actu-
al cholesterol concentrations measured in these lipopro-
tein preparations, no significant difference could be
detected between the lines fitting the LDL and HDL data
sets (Figure 1E). Altogether these results suggest that
cholesterol is a major mediator of the activation of p38
MAPKs by lipoproteins.
LDL-derived lipids activate the p38 MAPKs
If cholesterol is mediating the ability of lipoproteins to
stimulate the p38 MAPK pathway, the lipid fraction
extracted from LDLs, which contains unesterified and
esterified cholesterol, various phospholipids, and TGs,
but no proteins, should still stimulate the activation of the
p38 MAPKs. Figure 2A shows that, indeed, protein-
depleted LDL extracts are potent stimulators of this
pathway. Moreover, pure cholesterol solubilized in meth-
yl-b-cyclodextrin dose-dependently activated the p38
MAPKs (Figure 2B), further demonstrating the capacity
of cholesterol to stimulate this MAPK pathway. In con-
trast, the two main phospholipids borne by lipoproteins,
PC and sphingomyelin, did not have the capacity to acti-
vate the p38 MAPKs (Figure 2C and D). These results
indicate that it is the cholesterol moiety of lipoproteins
rather than the phospholipids that is required for p38
activation.
Phospholipid liposomes loaded with cholesterol
strongly activate the p38 MAPKs
In order to create a physiologically more relevant model
of lipoprotein particles and study the ability of cholesterol
to mediate the activation of the p38 MAPK pathway, we
generated phospholipid liposomes loaded or not with
cholesterol. Figure 3A shows that PC sonicated in the
presence or in the absence of cholesterol or cholesterol
esters formed liposomes, while sonication of cholesterol
alone did not. FACS analysis of the liposomes demon-
strated a large heterogeneity in size (Figure 3B), but both
small and large liposomes contained cholesterol provid-
ing that PC was sonicated in the presence of cholesterol
or cholesterol esters (Figure 3C). Activation of the p38
MAPK pathway was induced when cells were incubated
with PC liposomes containing cholesterol, but not in
response to liposomes made of PC alone or made of PC
and cholesterol esters (Figure 3D). These results show
that the presence of unesterified cholesterol in phospho-
lipid liposomes is essential for the activation of the p38
MAPK pathway.
LDLs with lower cholesterol content display reduced
ability to stimulate the p38 MAPK pathway
To assess the importance of the cholesterol moiety in
native LDL particles for the activation of the p38 MAPK
pathway, we modulated their cholesterol content by incu-
bating them in the presence of TGs. In these conditions,
exchange of cholesterol for TGs occurs (Granot et al.,
1985) reducing the cholesterol/protein ratio of the parti-
cles (Figure 4A, column on the right). The LDLs with lower
cholesterol content had a reduced ability to stimulate the
p38 MAPKs compared to native LDL particles (Figure 4A
and B). This suggests that cholesterol is the limiting com-
ponent in lipoprotein particles that activates the p38
MAPK pathway.
Perturbation of cholesterol levels in cellular
membranes stimulates the p38 MAPK pathway
Perturbation of the lipid plasma membrane composition
might be involved in activation of the p38 MAPK path-
way. To experimentally modulate the cholesterol content
of cell membranes, fibroblasts were incubated with the
cholesterol-depleting agent methyl-b-cyclodextrin (Furu-
chi and Anderson, 1998; Jans et al., 2004). As shown in
Figure 5, this compound induced p38 MAPK activity in a
dose-dependent manner. Stimulation of the p38 MAPKs
was also observed with nystatin, another cholesterol-
depleting agent (data not shown). Activation of the p38
MAPK pathway upon cholesterol depletion has been
reported in other cell types (e.g., keratinocytes) (Jans
et al., 2004). The observations that both cholesterol-load-
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Figure 1 Correlation between the cholesterol content in lipoproteins and activation of the p38 MAPK pathway.
(A) Human fibroblasts (GM00316B) were starved for 24 h in lipoprotein-free medium and stimulated with increasing concentrations
of LDLs (0, 50, 100, 200, 400, and 800 mg/ml) or HDLs (0, 100, 200, 400, 800 and 1600 mg/ml) for 10 min. The activation of p38
MAPKs was assessed by Western blot analysis using anti-phospho-p38 MAPK antibody. Total p38 MAPK expression was also
assessed by Western blot analysis.
(B) Starved human fibroblasts were stimulated with the indicated concentrations of LDLs and HDLs. The activation of the p38 MAPKs
was then determined as described in panel (A). The results correspond to the quantitation of the intensity of the phospho-p38MAPK
band and are expressed as the percent of the maximum stimulation (mean"standard deviation of five independent experiments).
(C) Theoretical composition of the indicated components in LDL and HDL particles. See text for details.
(D) The activation of p38 obtained in Figure 1B was expressed as a function of the theoretical amounts of cholesterol, phospholipids,
TGs, S1P and particle number present in LDL and HDL.
(E) The activation of p38 MAPKs induced by non-saturating concentrations of LDLs and HDLs (less than 1500 mg/ml) was expressed
as a function of the cholesterol concentrations measured in three independent LDL and HDL preparations (data are derived from four
independent experiments and presented as described in panel B). The best-fit regression lines for the LDL and HDL data points are
indicated. Linear regression analysis showed no significant difference between the slopes of these lines (ps0.34).
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Figure 2 Cholesterol, but not PC or sphingomyelin, activates p38.
(A) Human fibroblasts were starved as in Figure 1A and treated with LDL-derived lipids — 87, 174 and 348 mg/ml phospholipids (the
corresponding amounts of phospholipids found in 100, 200 and 400 mg/ml LDL-protein) for 10 min. The extent of p38 activation was
assessed as in Figure 1A. This experiment has been repeated seven times with similar results.
(B) Human fibroblasts were starved as above and treated with increasing concentrations of cholesterol solubilized in b-methyl-
cyclodextrin or 200 mg/ml LDL-protein for 10 min. The extent of p38 MAPK activation was then determined. Results are normalized
for p38 phosphorylation induced by the LDLs. The graph represents pooled data from three independent experiments.
(C) Human fibroblasts were starved as above and treated with increasing concentrations of PC (0, 174, 393, 768 mg/ml) for 10 min.
LDL-derived lipids were used as a positive control for p38 MAPK activation. The active form of p38 MAPK was detected as above.
This experiment was repeated 13 times with similar results.
(D) Human fibroblasts were starved as above and treated with increasing concentrations of sphingomyelin (SM) for 10 min. Activation
of the p38 MAPKs was detected as described above. LDLs (200 mg protein/ml) were used as a positive control for p38 MAPK
activation. This experiment was repeated two times with similar results.
ed vesicles and cholesterol-depleting agents stimulate
the p38 MAPK pathway suggest that increasing or low-
ering cholesterol levels in plasma membranes induces
activation of this pathway.
Activation of p38 MAPKs in response to LDLs and
cholesterol is detected in several blood vessel cell
types
To determine whether cell types found in blood vessels
other than fibroblasts could respond to elevated choles-
terol levels, a smooth muscle cell line (A-10) and an
endothelial cell line (HUVEC) were also analyzed. As
shown in Figure 6, native LDLs (panel A) and cholesterol-
containing PC liposomes (panel B), but not empty PC
liposomes (panel B), induced the activation of the p38
MAPK pathway in the three cell lines tested. These data
indicate that cell lines characteristic of major cell types
found in blood vessel walls (fibroblasts, smooth muscle
cells and endothelial cells) efficiently induce p38 MAPKs
in response to the cholesterol moiety found in
lipoproteins.
Contribution of other MAPK pathways to
lipoprotein-induced p38 MAPK activation
Finally, to determine if the JNK or the ERK MAPK path-
ways could modulate the activation of p38 MAPKs by
lipoproteins, various chemical inhibitors were employed:
SB 203580 that inhibits the p38 MAPKs (Davies et al.,
2000), SP 600125 that blocks all three JNK isoforms
(Bennett et al., 2001), and PD 98059 that inhibits MEK1,
an upstream activator of ERKs (Davies et al., 2000).
Dose-response analyses were first performed to deter-
mine at which concentrations these inhibitors specifically
block the relevant pathways. Serum, UV irradiation, and
hyper-osmolarity (0.5 M sorbitol) were used to activate
the ERK, JNK and p38 MAPK pathways, respectively.
Figure 7A shows that 3 mM SB 203580, 7 mM SP 600125,
and 5 mM PD 98059 efficiently inhibited the pathway they
were supposed to block but did not inhibit the other two
MAPK pathways. These doses of inhibitors were then
tested for their ability to modulate LDL-induced p38
MAPK activity. To measure the kinase activity of p38
MAPKs, phosphorylation of MAPKAP-2, a known p38
MAPK substrate, was assessed. The p38 MAPK inhibitor,
but not the ERK and JNK inhibitors, abrogated the ability
of p38 MAPKs to phosphorylate MAPKAP-2 in response
to LDL stimulation (Figure 7B). Therefore, lipoprotein-
induced p38 MAPK activity does not appear to be mod-
ulated by the JNK and the ERK MAPK pathways.
SB 203580, by competitively binding to the ATP pocket
of p38 MAPKs (Eyers et al., 1998), blocks their kinase
activity but should not prevent their phosphorylation by
upstream kinases. Figure 7B shows, however, that SB
203580 slightly reduced the ability of LDLs to induce p38
MAPK phosphorylation (the other inhibitors had no effect
on LDL-stimulated p38 MAPK phosphorylation). Since
p38 MAPK can undergo autophosphorylation in certain
conditions, which is blocked by SB 203580 (Ge et al.,
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Figure 3 PC liposomes containing unesterified cholesterol are potent activators of the p38 MAPKs.
(A) Phase contrast images of the indicated sonicated mixtures.
(B) Liposomes made of PC alone or PC and either cholesterol or cholesterol esters were submitted to FACS analysis (light gray
profile: PC only liposomes; dark gray profile: PC-cholesterol liposomes).
(C) 10 million of the small and large liposome vesicles indicated in panel (B) were purified using a cell sorter and their cholesterol
content measured.
(D) Human fibroblasts were starved as described in Figure 1A and treated for 10 min with PBS (control), PBS/0.1 mM EDTA (EDTA),
sonicated PBS/0.1 mM EDTA (sonic.), increasing concentrations of empty PC liposomes or PC liposomes containing cholesterol or
cholesterol esters. The amounts of liposomes used correspond to the PC content in the liposomes (100, 200, 400 and 800 mg/ml
PC or the corresponding volume of the supernatant of a cholesterol suspension in PBS wmockx). The cells were then lysed and
activation of the p38 MAPKs was assessed by Western blot analysis using anti-phospho-p38 MAPK antibody. The results are
expressed as fold increase relative to the control value (mean"SD of three independent experiments).
2002), it is possible that lipoproteins induce p38 MAPK
activity not only by stimulating the conventional p38
MAPK kinases (i.e., MKK3 and MKK6) but also by favor-
ing autophosphorylation of p38 MAPKs.
Discussion
Lipoproteins, which are the main cholesterol suppliers for
cells, are known to affect MAPK pathways in various cell
types (Gouni-Berthold and Sachinidis, 2002). However,
the nature of the components within the lipoprotein par-
ticles that mediate activation of the MAPK pathways has
not been clearly established. We have previously shown
that LDLs activate the p38 MAPK pathway in fibroblasts
in an LDL receptor-independent manner (Dobreva et al.,
2003). These results indicate that there are other recep-
tors for LDL particles that mediate their ability to activate
the p38 MAPKs or that the lipoproteins do not need to
be internalized to activate these MAPKs. In the latter
case, transfer of lipoprotein components to the plasma
membrane could be the biochemical event leading to
activation of the p38 MAPKs.
While some components of lipoproteins, including PC
and sphingomyelin, do not activate the p38 MAPK path-
way (Figure 2), other components of lipoproteins, or mol-
ecules carried by lipoproteins, have the potential to
stimulate this pathway. For example, some phospholipid
derivates, such as lysophosphatidylcholine (LPC) and
lysophosphatidic acid (LPA), can activate the p38 MAPK
pathway (Jing et al., 2000; Hayashi et al., 2001; Taka-
hashi et al., 2002). However, these components are either
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Figure 4 LDLs with lower cholesterol content display
decreased ability to activate the p38 MAPK pathway.
(A) Human fibroblasts were starved as described in Figure 1A
and treated with increasing concentrations of native LDLs or
LDLs with lower cholesterol content (see materials and meth-
ods). Activation of the p38 MAPKs was measured as described
in Figure 1A. Shown are representative blots from three different
sets of native LDL and LDLs with lower cholesterol content. The
cholesterol/protein ratios for each set are shown on the right.
(B) Quantitation of the data presented in panel (A). Results cor-
respond to the mean"SD of four independent experiments.
Figure 5 Depletion of cholesterol in plasma membranes induc-
es p38 MAPK activation.
Human fibroblasts were starved as above and treated with the
indicated concentrations of methyl-b-cyclodextrin for 10 min.
Activation of the p38 MAPKs was detected as described above.
Results are normalized to the value obtained with 10 mM cyclo-
dextrin and correspond to the average of four independent
experiments.
found in small amounts or not present at all in native LDL
particles. Since we did not detect oxidation in our LDL
preparations (data not shown; Dobreva et al., 2003) and
since oxidation of LDLs is not required for the activation
of the p38 MAPKs (Dobreva et al., 2003), it is unlikely
that LPC, LPA or other oxidized derivates of LDL com-
ponents play a major role in the modulation of the p38
MAPK pathway by native lipoproteins.
S1P is yet another phospholipid that has the potential
to mediate the activation of p38 MAPKs (Robert et al.,
2001). There is however no correlation between the abil-
ity of LDLs and HDLs to induce p38 MAPK activation
when their concentrations are expressed in terms of their
S1P content (Figure 1). In addition, the amount of S1P
necessary for the activation of the p38 MAPKs is well
above the concentrations found in native lipoproteins
(Robert et al., 2001). This suggests that although some
phospholipid derivates have the ability to activate the
p38 MAPKs at pharmacological concentrations they are
unlikely to be the main mediators of lipoprotein-induced
p38 MAPK activation.
The present study indicates that cholesterol is the main
lipoprotein component responsible for the activation of
the p38 MAPK pathway in three major cell types found
in blood vessels, i.e., fibroblasts, smooth muscle cells
and endothelial cells. Several observations support this
notion: (i) LDL and HDL have the same potency in induc-
ing p38 MAPKs when cholesterol, but not other com-
ponents, is used to express their concentration; (ii)
cholesterol solubilized in methyl-b-cyclodextrin or incor-
porated in phospholipid liposomes stimulates the p38
MAPKs, and (iii) reduction in the cholesterol content in
LDL particles diminishes their ability to stimulate the p38
MAPK pathway.
The mechanism used by lipoprotein cholesterol to
stimulate the p38 MAPKs is unclear at the present time.
LDL receptor family members do not seem to be involved
as lipoproteins efficiently stimulate the p38 MAPKs in
conditions where this receptor family is absent or inhib-
ited (Dobreva et al., 2003). In fact, lipoproteins may not
need to be internalized to deliver cholesterol to cell mem-
branes. For example, the scavenger receptor type BI
(SR-BI), while binding to lipoproteins, does not internalize
most of them (Fidge, 1999). However it does allow the
transfer of cholesterol from the particles to cellular mem-
branes (Fidge, 1999; Cherradi et al., 2001; Eckhardt
et al., 2004). This can lead to changes of the bio-physical
properties of these membranes (Brown and London,
2000) and modulation of various cellular and signaling
responses (Pike and Miller, 1998; Xavier et al., 1998;
Sheets et al., 1999; Incardona and Eaton, 2000). It is
known that cholesterol can affect receptor affinities and
activities of proteins with sterol-sensing domains (Incar-
dona and Eaton, 2000). Moreover, caveolaes and lipid
rafts, corresponding to membrane domains with
increased cholesterol content, are enriched in specific
signaling proteins and modulate several signaling path-
ways including the ERK MAPK (Furuchi and Anderson,
1998) and tumor necrosis factor (TNF)-induced nuclear
factor-kappa B (NF-kB) activation (Legler et al., 2003).
It will be important in the future to characterize the
mechanisms by which cholesterol in lipoproteins activate
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Figure 6 LDLs and cholesterol-containing liposomes activate the p38 MAPKs in fibroblasts, smooth muscle cells and endothelial
cells.
(A) GM00316, A-10 and HUVEC were starved as described in Figure 1A and treated with increasing concentrations of LDLs (0, 50,
100, 200, 400 mg/ml) or 0.1 mg/ml anisomycin (A; positive control for p38 MAPK activation) for 10 min. The cells were then lysed
and the activation of the p38 MAPKs was assessed by Western blotting using anti-phospho-p38 MAPK antibodies.
(B) GM00316, A-10 and HUVEC were starved as above and treated with increasing concentrations (0, 400, and 800 mg PC/ml) of
empty PC liposomes (PC) or PC liposomes containing cholesterol (PC:Ch) or 200 mg/ml LDL for 10 min. Activation of the p38 MAPKs
was measured as above.
the p38 MAPK pathway and determine the contribution
of this signaling event in the development of pathological
conditions, such as atherosclerosis, that arise from
increased lipoprotein blood levels.
Materials and methods
Materials
PC, sphingomyelin, cholesterol, cholesterol linoleate andmethyl-
b-cyclodextrin were obtained from Sigma (Buchs, Switzerland).
Alternatively, PC and cholesterol were obtained from Avanti
Polar Lipids (Alabaster, AL, USA). Anti-phospho-p38 (Thr180/
Tyr182), anti-p38 MAPK, anti-phospho-cJun (Ser73), anti-phos-
pho-ERK (Thr202/Tyr204) and anti-phospho-MAPKAP-2
(Thr334) antibodies were purchased from Cell Signaling Tech-
nology (Beverly, MA, USA). SB 203580, SP 600125 and PD
98059, were from Alexis Corporation (Lausen, Switzerland). They
were dissolved in DMSO as 10 mM, 20 mM and 50 mM stock
aliquots, respectively, and stored at y208C. The anti-RasGAP
antibody was also obtained from Alexis Corporation.
Cell culture
A-10 (rat smooth-muscle cells) and HUVEC were obtained from
ATCC (via LGC Promochem, Molsheim, France). GM00316B
human skin fibroblasts were purchased from Coriell Cell Repos-
itories (Camden, NJ, USA). A-10 and GM00316 were maintained
in Dulbecco’s modified Eagle’s medium (DMEM), supplemented
with 15% non-decomplemented fetal calf serum (FCS; Amimed,
Bioconcept, Allschwil, Switzerland) at 378C and 5% CO2.
HUVEC were cultured in F-12K medium (Kaighn’s modification
of Ham’s F-12, ATCC), containing 33.3 mg/ml endothelial cell
growth supplement (Sigma), 0.1 mg/ml heparin and 10% non-
decomplemented FCS.
Lipoprotein and lipoprotein-free serum preparation
and purification
LDL and HDL were isolated from human serum by sequential
density ultracentrifugation as described previously (Havel et al.,
1955; James and Pometta, 1990) and dialyzed for 48 h against
PBS containing 100 mM EDTA. Human lipoprotein-free serum
was prepared by removal of lipoproteins by ultracentrifugation
at a density of 1.23 g/l (James and Pometta, 1990). The protein
concentration was measured by Bradford assay using BSA as a
standard. The cholesterol concentration was measured by enzy-
matic in vitro test kit from Roche (Basel, Switzerland).
Preparation of lipid extracts
Total lipid extracts from LDL and HDL fractions were prepared
by chloroform:methanol (2:1) extraction of lyophilized lipopro-
teins (Olofsson et al., 1980) for 30 min at -208C. The solvent was
evaporated under nitrogen stream and the dried lipids were
resuspended by vortexing in PBS, 0.05% NaN3.
Preparation and characterization of phospholipid
liposomes loaded or not with cholesterol
PC, sphingomyelin, cholesterol and cholesterol linoleate were
dissolved in chloroform. For the preparation of liposomes in Fig-
ure 3, aliquots of the phospholipid and cholesterol stock solu-
tions wat a PC:cholesterol ratio of 1:2.5 (w/w) when these two
compounds were mixedx were dried under nitrogen stream and
resuspended in PBS, 100 mM EDTA (or 10 mM HEPES pH 7.4,
100 mM NaCl) at 558C. The samples were continuously vortexed
and the tubes were filled with nitrogen to avoid oxidation. The
resulting suspensions were sonicated in a sonication bath for
6 h at 558C. The presence of phospholipid liposomes was con-
firmed by taking pictures of the liposomes with a Zeiss Axioplan
2 microscope. The liposomes were purified by FACS.
In Figure 6, the phospholipid/cholesterol suspensions were
sonicated with a Branson tip sonifier for 10 min under temper-
ature control (max. 308C). The resulting clear opalescent prep-
arations were checked by photon correlation spectroscopy
(Malvern Zetasizer 4) for size distribution. Applying a multimodal
size distribution, the size heterogeneity was measured.
The amount of phosphate was measured as described (Chen
et al., 1956). Cholesterol incorporation was determined as men-
tioned above. MALDI-TOF MS analysis of the sonicated prepa-
rations did not indicate an additional formation of lysolipids and
other impurities of the samples.
Modification of the cholesterol content in LDL
LDLs were incubated with a preparation enriched in TGs for
6–8 h at room temperature with constant slow mixing. LDLs
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Figure 7 LDL-induced MAPKAP-2 phosphorylation is blocked by a specific p38 MAPK inhibitor.
Human fibroblasts were plated in six-well plates (60=103 cells/well) and the following day starved in serum-free DMEM for an
additional 24-h period. The cells were preincubated with the indicated concentration of SB 203580, SP 600125 and PD 98059 for
30 min and stimulated with serum (10% for 10 min), UV (60 J/m2 followed by a 1-h incubation) and sorbitol (0.5 M for 30 min). The
cells were then lysed and phosphorylation of ERKs, c-Jun, and MAPKAP-2 assessed by Western blotting. For c-Jun detection, the
cells were directly lysed in sample buffer, but this prevented accurate protein concentration measurement. A loading control (RasGAP)
is therefore also presented in this case (panel A). Alternatively, the cells, following the preincubation with the inhibitors, were stimulated
with 400 mg/ml LDL for 15 min (panel B). The active forms of MAPKAP-2 and p38 MAPKs were detected by Western blot analysis
using anti-phospho MAPKAP-2 (Thr 334) and anti-phospho-p38 MAPK antibodies. Shown are representative blots from five inde-
pendent experiments. The asterisk denotes a band that might correspond to phospho-JunD and the  symbol indicates a band that
could correspond to phospho-MAPKAP-3.
were re-isolated by centrifugation. This leads to an exchange of
TGs for cholesterol resulting in lipoproteins with lower choles-
terol content (Granot et al., 1985).
Western blot analysis
Cells were lysed in mono Q-C buffer (Yang and Widmann, 2001),
supplemented with 1 tablet of complete EDTA free protease
inhibitor per 50 ml (Roche). For the detection of phospho-cJun,
cells were directly lysed in sample buffer. Briefly, 60=103 cells
were plated in six-well plates, grown for 1 day and starved in
DMEM for an additional day. The cells were then subjected to
the treatments described in the figures, then washed once with
cold PBS and lysed in 70 ml of sample buffer (62.4 mM Tris–HCl
pH 6.8, 10% glycerol, 5% b-mercaptoethanol, 2% sodium
dodecyl sulfate, 0.01% bromophenol blue) on ice before being
loaded on SDS–PAGE.
Protein concentration was measured by Bradford assay using
BSA as a standard. Western blotting was performed as
described previously (Widmann et al., 1995) using a home-made
ECL reagent (Yang and Widmann, 2001). When quantitations
were performed, the primary antibody was revealed with a 1/
2500 dilution of an Alexa Fluor 680-conjugated anti-rabbit anti-
body (Molecular Probes, Eugene, OR, USA) or an IRDye
800-conjugated anti-mouse antibody (Rockland, Gilbertsville,
PA, USA) and subsequently visualized with the Odyssey infrared
imaging system (Licor, Homburg, Germany). Quantitation of the
bands was performed using the Odyssey infrared imaging
software.
Statistics
The statistics used in Figure 1 were performed with the SAS
System for Windows (SAS Institute Inc., Cary, NC, USA) using
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linear regression analysis and those used in Figure 4 were per-
formed with Microsoft Excel (XP edition) using the Student’s t-
test.
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